Efficacy of interactive manual dexterity training after stroke: a pilot single-blinded randomized controlled trial.


Journal

Journal of neuroengineering and rehabilitation
ISSN: 1743-0003
Titre abrégé: J Neuroeng Rehabil
Pays: England
ID NLM: 101232233

Informations de publication

Date de publication:
18 07 2023
Historique:
received: 06 01 2023
accepted: 10 07 2023
medline: 21 7 2023
pubmed: 19 7 2023
entrez: 18 7 2023
Statut: epublish

Résumé

To compare the efficacy of Dextrain Manipulandum™ training of dexterity components such as force control and independent finger movements, to dose-matched conventional therapy (CT) post-stroke. A prospective, single-blind, pilot randomized clinical trial was conducted. Chronic-phase post-stroke patients with mild-to-moderate dexterity impairment (Box and Block Test (BBT) > 1) received 12 sessions of Dextrain or CT. Blinded measures were obtained before and after training and at 3-months follow-up. Primary outcome was BBT-change (after-before training). Secondary outcomes included changes in motor impairments, activity limitations and dexterity components. Corticospinal excitability and short intracortical inhibition (SICI) were measured using transcranial magnetic stimulation. BBT-change after training did not differ between the Dextrain (N = 21) vs CT group (N = 21) (median [IQR] = 5[2-7] vs 4[2-7], respectively; P = 0.36). Gains in BBT were maintained at the 3-month post-training follow-up, with a non-significant trend for enhanced BBT-change in the Dextrain group (median [IQR] = 3[- 1-7.0], P = 0.06). Several secondary outcomes showed significantly larger changes in the Dextrain group: finger tracking precision (mean ± SD = 0.3 ± 0.3N vs - 0.1 ± 0.33N; P < 0.0018), independent finger movements (34.7 ± 25.1 ms vs 7.7 ± 18.5 ms, P = 0.02) and maximal finger tapping speed (8.4 ± 7.1 vs 4.5 ± 4.9, P = 0.045). At follow-up, Dextrain group showed significantly greater improvement in Motor Activity Log (median/IQR = 0.7/0.2-0.8 vs 0.2/0.1-0.6, P = 0.05). Across both groups SICI increased in patients with greater BBT-change (Rho = 0.80, P = 0.006). Comparing Dextrain subgroups with maximal grip force higher/lower than median (61.2%), BBT-change was significantly larger in patients with low vs high grip force (7.5 ± 5.6 vs 2.9 ± 2.8; respectively, P = 0.015). Although immediate improvements in gross dexterity post-stroke did not significantly differ between Dextrain training and CT, our findings suggest that Dextrain enhances recovery of several dexterity components and reported hand-use, particularly when motor impairment is moderate (low initial grip force). Findings need to be confirmed in a larger trial. Trial registration ClinicalTrials.gov NCT03934073 (retrospectively registered).

Identifiants

pubmed: 37464404
doi: 10.1186/s12984-023-01213-9
pii: 10.1186/s12984-023-01213-9
pmc: PMC10355015
doi:

Banques de données

ClinicalTrials.gov
['NCT03934073']

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

93

Informations de copyright

© 2023. The Author(s).

Références

Lancet. 2011 May 14;377(9778):1693-702
pubmed: 21571152
Neuropharmacology. 2000 Mar 3;39(5):835-41
pubmed: 10699448
Stroke. 2020 Mar;51(3):944-951
pubmed: 31906829
Neurorehabil Neural Repair. 2012 Jun;26(5):507-14
pubmed: 22275157
Neurorehabil Neural Repair. 2021 May;35(5):393-405
pubmed: 33745372
Brain. 2002 Apr;125(Pt 4):773-88
pubmed: 11912111
Muscle Nerve. 2007 Jun;35(6):788-92
pubmed: 17326120
J Neuroeng Rehabil. 2011 Nov 16;8:63
pubmed: 22087842
J Hand Ther. 2015 Oct-Dec;28(4):356-62; quiz 363
pubmed: 26206167
Brain Commun. 2022 Sep 23;4(5):fcac241
pubmed: 36262369
Neuroreport. 2012 Aug 1;23(11):663-7
pubmed: 22643236
Elife. 2022 Oct 18;11:
pubmed: 36255057
Neurophysiol Clin. 2019 Apr;49(2):149-164
pubmed: 30391148
J Neurophysiol. 2003 Aug;90(2):1160-70
pubmed: 12660350
Clin Rehabil. 1999 Aug;13(4):354-62
pubmed: 10460123
Stroke. 2003 Sep;34(9):2181-6
pubmed: 12907818
Stroke. 2019 Dec;50(12):3647-3649
pubmed: 31645211
JAMA. 2006 Nov 1;296(17):2095-104
pubmed: 17077374
J Neurophysiol. 2017 Aug 1;118(2):1151-1163
pubmed: 28566461
Schizophr Bull. 2019 Oct 24;45(6):1358-1366
pubmed: 30561714
Electroencephalogr Clin Neurophysiol. 1994 Aug;91(2):79-92
pubmed: 7519144
J Stroke Cerebrovasc Dis. 2016 Jul;25(7):1655-1664
pubmed: 27067882
Neurophysiol Clin. 2022 Oct;52(5):354-365
pubmed: 35945093
J Neurol Neurosurg Psychiatry. 2019 May;90(5):498-506
pubmed: 30770457
Ann Phys Rehabil Med. 2009 Apr;52(3):269-93
pubmed: 19398398
Neurorehabil Neural Repair. 2007 Jul-Aug;21(4):315-26
pubmed: 17353460
Clin Neurophysiol. 2002 Dec;113(12):2025-9
pubmed: 12464343
Neurology. 2017 Dec 12;89(24):2413-2421
pubmed: 29142090
Brain Res. 2012 May 3;1452:96-107
pubmed: 22464180
Neurorehabil Neural Repair. 2020 Oct;34(10):904-914
pubmed: 32830602
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
Front Hum Neurosci. 2014 Aug 22;8:662
pubmed: 25202258
Eur Radiol. 2016 Mar;26(3):733-42
pubmed: 26123409
Lancet Neurol. 2016 Sep;15(10):1019-27
pubmed: 27365261
Exp Brain Res. 2023 Jun;241(6):1501-1511
pubmed: 37085646
J Hand Ther. 2020 Apr - Jun;33(2):188-197
pubmed: 32446531
N Engl J Med. 2010 May 13;362(19):1772-83
pubmed: 20400552
Stroke. 2016 Oct;47(10):2596-602
pubmed: 27608819
Brain Stimul. 2017 Jul - Aug;10(4):721-734
pubmed: 28385535
Ann Phys Rehabil Med. 2022 May;65(3):101622
pubmed: 34929355
Stroke. 2005 Nov;36(11):2493-6
pubmed: 16224078
Stroke. 2021 Nov;52(11):3706-3717
pubmed: 34601901
Clin Neurophysiol. 2018 Apr;129(4):797-808
pubmed: 29453171
Annu Rev Neurosci. 2008;31:195-218
pubmed: 18558853
Neurorehabil Neural Repair. 2020 Aug;34(8):733-745
pubmed: 32845230
Brain Res Bull. 2006 Jun 15;70(1):1-7
pubmed: 16750476
Arch Phys Med Rehabil. 2001 Jan;82(1):14-9
pubmed: 11239280
J Neuroeng Rehabil. 2015 Aug 02;12:64
pubmed: 26233571
Cortex. 2016 Dec;85:1-12
pubmed: 27770667
Am J Occup Ther. 1985 Jun;39(6):386-91
pubmed: 3160243
J Neurosci. 2010 Mar 17;30(11):4102-9
pubmed: 20237280
Neurology. 2009 May 19;72(20):1766-72
pubmed: 19451532
Neurology. 2021 Aug 17;97(7):e706-e719
pubmed: 34400568
PLoS One. 2016 May 06;11(5):e0154792
pubmed: 27152853
Front Neurol. 2018 Oct 29;9:910
pubmed: 30420830
J Neurosci. 2020 Sep 30;40(40):7651-7667
pubmed: 32873722
J Neuroeng Rehabil. 2014 Apr 30;11:76
pubmed: 24885076

Auteurs

Maxime Térémetz (M)

Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Université Paris Cité, 102-108 Rue de La Santé, 75014, Paris, France.

Sonia Hamdoun (S)

Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Université Paris Cité, 102-108 Rue de La Santé, 75014, Paris, France.
Service de Médecine Physique et de Réadaptation, Groupe Hospitalier Universitaire Paris, Psychiatrie et Neurosciences, 1 Rue Cabanis, 75014, Paris, France.

Florence Colle (F)

SSR Neurologique, Hôpitaux de Saint-Maurice, 12/14 Rue du Val d'Osne, 94410, Saint-Maurice, France.

Eloïse Gerardin (E)

Neurology Department, Stroke Unit, UCLouvain/CHU UCL Namur (Godinne), Yvoir, Belgium.

Claire Desvilles (C)

Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Université Paris Cité, 102-108 Rue de La Santé, 75014, Paris, France.

Loïc Carment (L)

Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Université Paris Cité, 102-108 Rue de La Santé, 75014, Paris, France.

Sylvain Charron (S)

Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Université Paris Cité, 102-108 Rue de La Santé, 75014, Paris, France.

Macarena Cuenca (M)

Centre de Recherche Clinique, Groupe Hospitalier Universitaire Paris, Psychiatrie et Neurosciences, 1 Rue Cabanis, 75014, Paris, France.

David Calvet (D)

Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Université Paris Cité, 102-108 Rue de La Santé, 75014, Paris, France.
Service de Neurologie, Groupe Hospitalier Universitaire Paris, Psychiatrie et Neurosciences, 1 Rue Cabanis, 75014, Paris, France.
FHU NeuroVasc, Paris, France.

Jean-Claude Baron (JC)

Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Université Paris Cité, 102-108 Rue de La Santé, 75014, Paris, France.
Service de Neurologie, Groupe Hospitalier Universitaire Paris, Psychiatrie et Neurosciences, 1 Rue Cabanis, 75014, Paris, France.
FHU NeuroVasc, Paris, France.

Guillaume Turc (G)

Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Université Paris Cité, 102-108 Rue de La Santé, 75014, Paris, France.
Service de Neurologie, Groupe Hospitalier Universitaire Paris, Psychiatrie et Neurosciences, 1 Rue Cabanis, 75014, Paris, France.
FHU NeuroVasc, Paris, France.

Marc A Maier (MA)

Université Paris Cité, CNRS, Integrative Neuroscience and Cognition Center, 75006, Paris, France.

Charlotte Rosso (C)

Institut du Cerveau et de la Moelle Épinière, ICM, Inserm U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.

Jean-Louis Mas (JL)

Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Université Paris Cité, 102-108 Rue de La Santé, 75014, Paris, France.
Service de Neurologie, Groupe Hospitalier Universitaire Paris, Psychiatrie et Neurosciences, 1 Rue Cabanis, 75014, Paris, France.
FHU NeuroVasc, Paris, France.

Påvel G Lindberg (PG)

Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Université Paris Cité, 102-108 Rue de La Santé, 75014, Paris, France. pavel.lindberg@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH